Opus Genetics Appoints Ben Yerxa, Ph.D., as Permanent

Opus Genetics Appoints Ben Yerxa, Ph.D., as Permanent

Industry veteran and experienced CEO will continue to lead the company as its AAV-based gene therapies for inherited retinal diseases approach the clinic RESEARCH TRIANGLE PARK, NC, June 21, 2022 (GLOBE NEWSWIRE) — Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced the appointment of Ben Yerxa, Ph.D., as … Read more